Australia’s trusted independent immunisation experts

Publications

Marshall HS, Wood N. The potential for improved protection against pertussis [Editorial]. The Lancet Infectious Diseases. 17 July 2020 . [Abstract]

Rashid H, Dey A, Manocha R, Tashani M, Macartney K, Beard F. Australia’s national zoster vaccination program: Knowledge, attitudes and behaviour of general practitioners. Communicable Diseases Intelligence. 2020;44. [Full text]

Top KA, Macartney K, Bettinger JA, Tan B, Blyth CC, Marshall HS, Vaudry W, Halperin SA, McIntrye P. Active surveillance of acute pediatric hospitalisations demonstrates the impact of vaccination programs and informs vaccine policy in Canada and Australia. Eurosurveillance. 2020;25:pii=1900562. [Full text]

Glover C, Crawford N, Leeb A, Wood N, Macartney K. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety. Vaccine. 2020;38:4892-4900 . [Abstract]

McRae JE, Quinn HE, Saravanos GL, Carlson SJ, Britton PN, Crawford NW, Wood NJ, Marshall HS, Macartney KK on behalf of the PAEDS network. Paediatric Active Enhanced Disease Surveillance (PAEDS) 2017 and 2018: Prospective hospital-based surveillance. Communicable Diseases Intelligence. 2020;44 . [Full text]

Litt J, Booy R, Bourke D, Dwyer DE, Leeb A, McCloud P, Stein AN, Woodward M, Cunningham AL. Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2020.1754702. [Full text]

Sharma K, Perrett K, Wood N. Case Series: Yellow fever vaccination in egg-allergic children. Pediatric Infectious Disease Journal. 2020;39:e76-e78. doi: 10.1097/INF.0000000000002625. [Full text]

Totterdell J, Phillips A, Glover C, Chidwick K, Marsh J, Snelling T, Macartney K. Safety of live attenuated herpes zoster vaccine in adults 70 to 79 years: a self-controlled case series analysis using primary care data from the MedicineInsight program. Vaccine. 2020;38:3968-3979 . [Full text]

Pillsbury AJ, Fathima P, Quinn HE, Cashman P, Blyth CC, Leeb A, Macartney K . Comparative post-market safety profile of adjuvanted and high-dose influenza vaccines in the elderly. JAMA Open. 2020;3(5):e204079 . [Full text]

Deng L, Mab A, Wood N, Ardern-Holmes S. Vaccination management in an asymptomatic child with a novel SCN1A variant and family history of status epilepticus following vaccination: a case report on a potential new direction in personalised medicine. Seizure: European Journal of Epilepsy. 2020;78:49-52 . [Full text]